Affimed N.V. (AFMD)
Symbol Info
Listed Symbol AFMD
Name Affimed N.V.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $27,275,193
Latest Fiscal EPS $-0.37
Price Info
21 Day Moving Average $3.1160
21 Day EMA $2.934010
50 Day Moving Average $2.9385
50 Day EMA $2.981320
200 Day EMA $3.130190
200 Day Moving Average 3.279900
52 Week High $5.08
52 Week Low $2.52
52 Week Change $-17.220500
Alpha 0.009788
Beta 2.8995
Standard Deviation 0.339768
R2 0.085976
Periods 60
Share Information
10 Day Average Volume 480,386
20 Day Average Volume 658,985
30 Day Average Volume 605,382
50 Day Average Volume 545,159
Outstanding Shares 62,440,213
Float Shares 62,440,213
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 161
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 4,821,016
Institute Holdings Percent 66.400000
Institute Sold Previous 3 Months 2,111,982
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $-0.1400001
7 Day Percent Change -4.86%
21 Day Price Change $-0.6900001
21 Day Percent Change -20.12%
30 Day Price Change $-0.1800001
30 Day Percent Change -6.16%
Month To Date Price Change $-0.2
Month To Date Percent -6.80%
90 Day Price Change $-0.24
90 Day Percent Change -8.05%
Quarter To Date $-0.2
Quarter To Date Percent -6.80%
180 Day Price Change $-1.4
180 Day Percent Change -33.82%
200 Day Price Change $-1.26
200 Day Percent Change -31.50%
Year To Date $-0.37
Year To Date Percent -11.90%
Profile
Description Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. It is also developing single and combination therapies to treat cancers and other life-threatening diseases.
Details
Issue Type CS
Market Cap $171,086,184
Sec Type EQS
Auditor KPMG AG Wirtschaftspruefungsgesellschaft
Total Shares Outstanding 62,440,213
CEO Adi Hoess
Employees 103
Last Audit UE
Classification
CIK 0001608390
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address Technologiepark
Im Neuenheimer Feld 582
Heidelberg, 69120
Website https://www.affimed.com
Facisimile +49 6221674364
Telephone +49 6221674360
Email ir@affimed.com
Key Ratios
Profitability
EBIT Margin -28.9
EBITDA Margin -27.2
Pre-Tax Profit Margin -475.6
Profit Margin Cont 1.76
Gross Margin -
Profit Margin TOT 1.76
Income Statements
Revenue $43,622,340
Revenue Per Share $0.6986
Revenue 3 Years $70.24
Revenue 5 Years $27.92
Valuation Measures
PE Ratio -
Enterprise Value $92,528,671
Price To Sales 3.921985
Price To Free Cash 2.700000
PE High Last 5 Years -
Price To Book 4.8
Price To Cash Flow 3.4
PE Low Last 5 Years -
Price To Tangible Book 4.6
Financial Strength
Total Debt To Equity 0.1
Int Coverage -16.8
Current Ratio 3.5
Leverage Ratio 3.5
Quick Ratio 3.4
Long Term Debt To Capital 0.02
Assets
Receivables Turnover 29.1
Invoice Turnover -
Assets Turnover 0.50
Management Effectiveness
Return Assets -14.67
Return On Equity -28.92
Return On Capital -24.51
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AFMD
Affimed NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.